Indian drugmakers lagging in vast vaccines market, but some progress being made

10 December 2019

Indian pharma does not offer serious competition to multinationals in terms of vaccines. With the government coming up with compulsory annual healthcare programs in India, there is a huge market for vaccines which no Indian pharma company has been able to capture, reports The Pharma Letter’s India correspondent.

Seven months after vaccine manufacturer Bharat Biotech acquired Chiron Behring Vaccines Pvt from GlaxoSmithKline (LSE: GSK), it has launched ChiroRab, an anti-rabies vaccine, thereby becoming the largest rabies vaccine manufacturer in the world.

Earlier marketed under the trade name Rabipur, ChiroRab has been evaluated in over 25 controlled clinical trials in five countries in more than 7,000 subjects.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK